cell

Swiss pharmaceutical company Roche has received accelerated approval from the US Food and Drug Administration (FDA) for the use of Tecentriq (atezolizumab), to treat locally advanced or metastatic urothelial carcinoma (mUC).

The drug can be administered on patients whose disease has progressed during or following platinum-based chemotherapy, or whose disease has worsened within 12 months of receiving platinum-based chemotherapy either before surgery (neoadjuvant) or after surgery (adjuvant).

Urothelial carcinoma is a serious cause for all bladder cancers and can be found in the ureter, renal pelvis and urethra.

Tecentriq is a monoclonal antibody that can directly bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, thereby preventing its interactions with both PD-1 and B7.1 receptors.

Atezolizumab can allow the activation of T cells by inhibiting PD-L1.

"We thank the scientists, doctors, patients and their families who made it possible to bring Tecentriq to people with advanced urothelial carcinoma."

Roche global product development head and chief medical officer Sandra Horning said: "Tecentriq is a new medicine that can work with the immune system to treat people with a type of bladder cancer that progressed after platinum-based chemotherapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We thank the scientists, doctors, patients and their families who made it possible to bring Tecentriq to people with advanced urothelial carcinoma."

The FDA’s accelerated approval programme facilitates conditional approval of a medicine that meets an unmet medical need for a serious condition, which is dependent on early evidence suggesting clinical benefit.

The current FDA approval of Tecentriq is based on the Phase II IMvigor 210 study.


Image: Histopathology of bladder urothelial carcinoma. Photo: courtesy of KGH